Investigational drug · Phase 3
YY001
Also called: Recombinant botulinum toxin type A, Rcombinant botulinum neurotoxin type A
Not approved by FDA. In 3 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Upper Limb Spasticity, Moderate to Severe Glabellar Lines.
Phase 3Last checked: Nov 19, 2026Latest source record: Jun 29, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
3
2 still active
All registered trials
6
Any phase or sponsor naming "YY001"
First trial start
2024
Mar 19, 2024
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "YY001", any sponsor or status.
Conditions studied
As listed on its trial records.
- Upper Limb Spasticity
- Moderate to Severe Glabellar Lines
Largest trials
Live from ClinicalTrials.gov: studies naming "YY001" as an intervention, largest first.
- A Phase III Study to Evaluate the Efficacy and Safety of Recombinant Botulinum Toxin Type A for Injection in the Treatment of Moderate to Severe Glabellar LinesPivotal-lookingCompleted
Chongqing Claruvis Pharmaceutical Co., Ltd.Industry
NCT06499688 · 529 participants · Start Dec 28, 2023 · Primary completion Mar 29, 2024
Drug: Rcombinant botulinum neurotoxin type A for injection (YY001); OnabotulinumtoxinA and 1 more · For: Moderate to Severe Glabellar Lines
Sites: Guangzhou, China; Wuhan, China; Changsha, China · 16 sites in all
- A Study on the Efficacy and Safety of Repeated Treatments With Recombinant Botulinum Toxin Type A for Injection in the Treatment of Moderate to Severe Glabellar LinesPivotal-lookingCompleted
Chongqing Claruvis Pharmaceutical Co., Ltd.Industry
NCT06583486 · 488 participants · Start Mar 19, 2024 · Primary completion Aug 25, 2025
Drug: Rcombinant botulinum neurotoxin type A for injection (YY001) · For: Moderate to Severe Glabellar Lines
Sites: Guangzhou, China; Wuhan, China; Changsha, China · 16 sites in all
- A Study on Recombinant Botulinum Toxin Type A (YY001) for Injection in Multiple Treatments of Adult Upper Limb SpasticityPivotal-lookingRecruiting
Chongqing Claruvis Pharmaceutical Co., Ltd.Industry
NCT07478822 · 300 participants (planned) · Start Mar 27, 2026 · Primary completion Jun 1, 2027
Drug: Recombinant botulinum toxin type A for injection (YY001) · For: Upper Limb Spasticity
Sites: Beijing, China; Chengdu, China; Guangdong, China · 16 sites in all
- A Clinical Study on Recombinant Botulinum Toxin Type A (YY001) for Injection in The Treatment of Upper Limb Spasticity in AdultsPivotal-lookingRecruiting
Chongqing Claruvis Pharmaceutical Co., Ltd.Industry
NCT06783114 · 254 participants (planned) · Start Sep 14, 2024 · Primary completion Sep 30, 2026
Drug: Recombinant Botulinum Toxin Type A for injection (YY001); BOTOX® and 1 more · For: Upper Limb Spasticity
Sites: Hefei, China; Beijing, China; Chongqing, China · 24 sites in all
- A Phase I/II Study of Recombinant Botulinum Toxin Type A for the Treatment of Moderate to Severe Glabellar LinesPivotal-lookingCompleted
Chongqing Claruvis Pharmaceutical Co., Ltd.Industry
NCT05743634 · 140 participants · Start Mar 22, 2022 · Primary completion Feb 13, 2023
Drug: YY001; OnabotulinumtoxinA and 1 more · For: Moderate to Severe Glabellar Lines
Sites: Beijing, China; Chongqing, China; Guangzhou, China · 6 sites in all
Shanghai Yuyao Biotech Co., Ltd.Industry
NCT06228846 · 16 participants · Start Jul 14, 2022 · Primary completion Apr 30, 2024
Drug: YY001 · For: Advanced Solid Tumor
Sites: Shanghai, China
Newest research
PubMed records naming it or its code names, newest first.
- Recombinant versus native botulinum neurotoxin type A: structural and pharmacodynamic comparison.
Yao Z, Xu L, Lu Y, et al. · Acta Crystallogr F Struct Biol Commun 2026
- Safety and efficacy of recombinant botulinum toxin type A (Eveotox®) in patients with post-stroke upper limb spasticity: Results from a Phase Ib/II clinical trial.
Lu R, Jin L, Xiong J, et al. · Toxicon 2026
- Therapeutic Efficacy and Safety of Recombinant Botulinum Toxin Type A for Moderate to Severe Glabellar Lines: A Randomized, Controlled, Double-blind, Phase III Trial in Chinese Adults.
Wu Y, Long X, Yu N, et al. · Aesthet Surg J 2026
- Safety and Efficacy of Recombinant Botulinum Toxin Type A for Moderate-to-severe Glabellar Lines: A Multicenter Randomized Controlled Trial.
Li Q, Long X, Xu C, et al. · Plast Reconstr Surg 2026
- Plesiomonas shigelloides infection induced ferroptosis and apoptosis in hepatopancreas of zig-zag eel (Mastacembelus armatus).
Yu Z, Yin X, Zhu W, et al. · Fish Shellfish Immunol 2025
- Remodeling the immune microenvironment for gastric cancer therapy through antagonism of prostaglandin E2 receptor 4.
Guo M, Hu P, Xie J, et al. · Genes Dis 2024
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.